Introduction: Ki-67 proliferation index (Ki-67 index) is used to quantify cell proliferation during histopathological assessment of various tumors including glioblastoma (GB).
INTRODUCTION
Glioblastoma (GB) is the most common malignant primary tumor of the central nervous system (CNS) and accounts for approximately 12-15% of all intracranial tumors. 1, 2 Unfortunately, it is also the most aggressive tumor of the CNS and has one of the worst prognoses of any cancer with a reported median survival of approximately 12 months. Multiple known factors play a role in determining prognosis. These include performance status at presentation, age, extent of surgical resection, methylation status of O-6-methylguanine-DNA methyltransferase and completion of a standardized chemo-radiotherapy protocol. 3 In addition, there may be other unknown clinical and molecular factors such as IDH mutation status (which was introduced as standard practice toward the end of our study period) that affect overall survival in GB.
As a result, clinicians are often unable to give accurate estimations of prognosis to their patients and this may have substantial implications on the treatment options discussed with patients and the treatment decisions reached by patients. Information regarding prognosis also has implications on patients' psychological state as well as their personal, financial and legal planning. 4 The Ki-67 protein is a cellular marker associated with ribosomal RNA transcription and thus cell proliferation. The Ki-67 protein is detected within the cell nucleoplasm during interphase and is relo- the Ki-67 proliferation index (Ki-67 index) as an independent prognostic factor of overall survival, there appears to be conflicting evidence regarding the association between the Ki-67 index and overall survival in GB.
We aimed to determine whether there was a correlation between Ki-67 index and overall survival in our 10-year series of patients with GB. We then aimed to determine a cut-point for Ki-67 index that predicted for poorer survival. 
MATERIAL AND METHODS

Following
Examination of histopathological specimens
The histopathological specimens (paraffin blocks and slides) from all eligible patients were retrieved from archive and re-examined independently by two neuro pathologists (WV and TN) working at the Institute of Clinical Pathology and Medical Research (ICPMR). In addition to verifying the diagnosis of GB, the two pathologists independently also interpreted the Ki-67 index for each histological specimen, using a manual cell counting approach. The two independent pathologist reviews were conducted to account for interobserver variability. Both pathologists were blinded to patient identifying information and results of the other pathologist's Ki-67 interpretations. Also, each pathologist interpreted each specimen on three separate occasions in order to account for intra-observer variability. An average was taken over the three observations by each pathologist and a subsequent average between the pathologists was made to assign the final Ki-67 index for each patient. If there was a difference in means of 25% or more, both pathologists agreed to review each slide to report a consensus figure.
Statistical analysis
The primary endpoint of the study was death and overall survival calculated from time of diagnosis to death. For each patient, the final Ki-67 index score (as a continuous variable) was analyzed for correlation with overall survival. Then the minimum P-value approach was employed to determine the cut-point value of the Ki-67 index that could significantly separate (smallest P-value) the patients into two groups (poorer survival vs better survival; ref. 5 ). This P-value was obtained using the log-rank test. Time-to event based on the optimal cut-point was described using the method of Kaplan-Meier. Statistical analysis was 
RESULTS
Of the eligible 71 patients (median age = 58, range 18-87), 41 (58%)
were male and 30 (42%) were female (Table 1) . Fifty-two (73%) patients were of ECOG performance status 0-1, whereas the rest (27%) were ECOG 2 or higher. Forty-six (65%) patients had died by the end of the study follow up period. The median overall survival for those who died during the follow-up period was found to be 9.02 months (range 0.32-63.2 months). The median time to last follow up for those who were alive was found to be 9.01 months (range 0.23-71.6 months).
The median Ki-67 index in the entire cohort was 21.9% (range: 4-80%). Of those who had experienced the primary endpoint of death, the median Ki-67 index was 20.1% (range 4.0-51.4%) as compared to 24.2% (range 5.0-80%) in those who were alive at final follow up.
Female patients experienced statistically significant greater overall survival (HR = 0.48; 95% CI, 0.26-0.87; P = 0.02) compared to male patients, as demonstrated in Figure 1 . There was a correlation between age and overall survival with univariate analysis demonstrating a statistically significant increase in hazard ratio for each year of age (HR = 1.03; 95% CI, 1.01-1.05; P = 0.0078).
There was statistically significant difference in overall survival between patients with ECOG status 0-1 and those with ECOG ≥ 2 (poorer overall survival). On univariate analysis (Figure 2 ), we identified a hazard ratio of 3.22 (95% CI, 1.63-6.36; P = 0.0008).
In our study, 46 (64.8%) patients were noted to have had under- In terms of radiotherapy dose received, 33(46.5%) patients received biologically effective doses of less than 60 Gy (in 2 Gy per fraction) compared to 38 (53.5%) patients who received biologically effective doses of 60 Gy (2 Gy per fraction). In univariate analysis (Figure 4 ), we found that those patients who received 60 Gy had statistically significant increased survival compared to those than received less than this (log-rank P < 0.0001; HR = 0.179).
High Ki-67 proliferation index correlated with a longer survival.
In patients with Ki-67 > 22% (n = 36), 5-year survival was approximately 30% compared to those with Ki-67 of ≤22% (n = 35) with survival of 5% (log-rank P-value = 0.04; HR = 0.53; 95% CI, 0.29-0.97; Figure 5 ). After fitting all outcome variables into a proportional hazards model (age, sex, ECOG status, chemotherapy, radiotherapy, Ki-67 proliferation index), age, ECOG status ≥2 and Ki-67 proliferation index <22% were statistically significant predictors for poorer overall survival. The findings from this study demonstrate a positive correlation between Ki-67 index and overall survival in GB. We found a statistically significant difference in overall survival between those whose tumors had a Ki-67 index of 22% or more (30% 5-year survival) versus those whose tumors had a Ki-67 index of < 22% (5% 5-year survival). To our knowledge, this is only the second study in the literature that has found a positive relationship between a higher Ki-67 index and improved overall survival. Although there were suggestions that chemotherapy use and radiotherapy dose were associated with overall survival, we believe, these were likely partly surrogates for ECOG performance status. Patients who were suitable for concurrent chemotherapy or higher radiotherapy doses were likely of better performance status.
Previous studies have attempted to quantify the relationship between the Ki-67 index and survival in patients with GB. Bouvier et al.
studied a cohort of 63 GB patients and attempted to determine if Ki-67 staining was associated with postoperative survival but were unable to identify a relationship. 6 They suggested that this is could be attributed to significant regional heterogeneity in these tumors. Bredel et al., in their cohort of 114 GB patients, found that patients with a high Topoisomerase IIa (TIIa), another proliferation index, as well as a Ki-67 index of > 27% had a significantly prolonged survival in a log-rank test in a univariate model. 7 To explain these findings, it was proposed that tumors with increased proliferation may be more prone to the cytotoxic effects of chemoradiotherapy, reminiscent of other highly proliferative tumor types such as lymphoma. 8 Other studies have found a similar association with small cell lung cancer and breast cancer. 9, 10 The findings in this study certainly appear to support this hypothesis. proposal that increased Ki-67 proliferation is a predictor of poorer progression free and overall survival in intracranial glioma. 13 In this metaanalysis, only 23 studies included patients with GB and of these only 10 consisted solely of GB patients. Of these 10 studies, there was no consistent Ki-67 cutoff used (range between 1.5% and 35%). Furthermore, only seven of these studies independently demonstrated a statistically significant difference in progression-free survival and none of them demonstrated a difference in overall survival.
In light of the above data in the literature, the findings of this study add to the uncertainly regarding the usefulness of Ki-67 as a prognostic factor in GB. One of the major limitations with the use of the Ki-67 proliferation index is of inter-and intraobserver variability. We attempted to overcome this through re-examination of all specimens by two independent neuro pathologists and on repeated occasions. These measures likely minimized the impact of inter-and intraobserver variability in Ki-67staining quantification. In addition, the most reliable, albeit time-consuming manual counting technique for Ki-67 was used in this study. 18 These above points are major strengths of our study. We do acknowledge, however, that the results pertaining to specific Ki-67 values may not be directly translatable to other clinical services due to differences in laboratory measurement techniques. Therefore, a Ki-67 index cutoff value of 22% may not be a universally adoptable Ki-67 index score that can be used at other centers.
We recognize that our study has limitations. In addition to the retrospective collation of the patient and disease outcome variables, the small patient cohort size and changes in GB management that occurred in during the study period are important considerations. Particularly given that key prognostic factors such as MGMT or IDH status as well as extent of surgical resection were not recorded in the earlier patients and therefore could not be assessed in our study. Nevertheless, our study results present an interesting, counter-intuitive finding that warrants further investigation, perhaps in the first instance through larger retrospective studies involving multiple cancer treatment and pathology centers.
CONCLUSIONS
There was a correlation between percentage staining of Ki-67 and overall survival in our cohort of patients with GB. We demonstrate that percentage Ki-67 staining <22% predicts for poorer survival in GB. This is only the second observational study documenting a positive correlation between Ki-67 and overall survival.
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